RESEARCH · GLOW BLEND · DERMAL WOUND MODELS
GLOW BLEND Components in Dermal Wound-Healing Models: BPC-157, Thymosin Beta-4 Fragments and GHK-Cu Compared
PurixLab’s GLOW BLEND 70mg is a research vial with the labelled composition BPC-157 10mg + TB-500 10mg + GHK-Cu 50mg. Our earlier articles cover the composition and component overview, thymosin beta-4 and actin sequestration and the combination and copper-chemistry questions. This article takes one model family, skin and dermal wound healing, and asks component by component which wound models were used, which endpoints were measured and how comparable the results are. The material is supplied for laboratory research use only, and nothing here describes effects of any PurixLab product.
Wound models are not interchangeable
Published skin-repair studies use very different systems. Incisional wounds are judged mainly by tensile strength; full-thickness excisional wounds by closure, re-epithelialisation and contraction; burns by necrosis and regrowth; and implanted sponges or wound chambers by the amount and composition of granulation tissue. Diabetic db/db mice, aged animals and ischaemic skin flaps model impaired healing. A positive result in one system does not predict a result in another, which matters when three components were each tested in different ones.
BPC-157: incisions, sponges and burns
An early rat study tested the pentadecapeptide in skin incisional wounds, colon-colon anastomoses and a sponge-implantation angiogenesis model, scoring collagen, reticulin and blood vessels, and reported significant differences from controls with both intragastric and local application [1]. In a later sponge study the number of new endothelial spaces increased not only with BPC-157 but also with the H2-blockers, omeprazole and sucralfate, whereas extra granulation tissue at 3 days was seen with BPC-157 and sucralfate but not the H2-blockers [2], so angiogenesis in that model was not specific to the peptide.
In mice with deep partial-thickness burns covering 20% of the body surface, a topical cream reduced oedema, inflammatory cells and necrosis, increased capillaries and collagen, reversed poor re-epithelialisation at two weeks and increased breaking strength; the silver sulfadiazine comparator improved only collagen formation and inflammatory cell numbers [3]. In an alkali-burn rat model from a different research group, topical treatment accelerated closure, with better granulation tissue, re-epithelialisation and collagen deposition at day 18, higher VEGF expression, and ERK1/2-linked proliferation, migration and tube formation in endothelial cells [4]. One study used an approved growth factor as the comparator: PL 14736, whose published sequence (GEPPPGKPADDAGLV) is that of BPC-157, showed similar selectivity to PDGF-BB (becaplermin) for granulation tissue in rat sponges and db/db excisional wounds and was more active in early collagen organisation [5]. A 2021 review led by the first author of that early incisional study gathers incisional, excisional, burn, diabetic-ulcer and alkali-burn work [6]. We found no controlled human skin-wound trial of BPC-157 in a PubMed search in October 2026.
Thymosin beta-4 and the LKKTETQ fragment
For the full-length protein, the founding rat full-thickness study reported faster re-epithelialisation, at least 11% more contraction by day 7, more collagen deposition and angiogenesis, and stimulated keratinocyte migration [7]. In db/db diabetic mice, treatment increased contraction and collagen deposition but not keratinocyte migration, since all diabetic animals had almost complete coverage at 8 days; in 26-month-old mice it increased migration, contraction and collagen [8]. In diabetic burn wounds it improved closure, granulation and vascularisation and lowered the receptor for advanced glycation end products [9].
The fragment question is directly relevant to TB-500. The same 2003 study reported that a seven-amino-acid synthetic peptide, LKKTETQ, duplicating the actin-binding domain, promoted repair in aged mice comparable to the parent molecule [8]. Separate work found the actin-binding motif essential for angiogenic activity, with near-identical activity to the full protein at about 50 nM in endothelial migration and aortic-sprouting assays [10], and the central 17-23 domain carried all of the matrix metalloproteinase-inducing activity in mouse wounds, where MMP-2 and -9 rose several-fold on day 2 [11]. The material sold as TB-500, however, was identified as the N-terminally acetylated form, Ac-LKKTETQ [12]; the wound abstracts above describe the non-acetylated sequence.
Full-length thymosin beta-4 is the only component here with randomised phase 2 skin data. In a European trial in 73 patients with venous stasis ulcers, topical treatment was comparable to placebo for safety [13], and a review of two phase 2 trials in stasis and pressure ulcers reported healing almost a month faster among patients who healed [14]. Neither tested the fragment.
GHK-Cu: matrix accumulation and remodelling
The copper tripeptide’s wound record centres on the extracellular matrix. In rat wound chambers, it produced concentration-dependent increases in dry weight, DNA, protein, collagen and glycosaminoglycans, with type I and III collagen mRNAs raised but not TGF-beta mRNA, while a control tripeptide had no effect [15]. In cultured dermal fibroblasts it increased MMP-2 along with TIMP-1 and TIMP-2, an effect reproduced by copper ions but not by GHK alone [16]. In twenty-four rats with full-thickness wounds inside an ischaemic skin flap, a topical gel reduced wound area by 64.5% by day 13 against 45.6% with vehicle and 28.2% without treatment, and treated wounds contained less TNF-alpha, MMP-2 and MMP-9 [17]. Biotinylated GHK bound to a collagen film improved contraction in normal and diabetic rats and raised local copper ninefold [18,19]. In humans, a randomised, vehicle-controlled trial in diabetic neuropathic ulcers reported 98.5% median closure against 60.8% with vehicle and fewer infections [20].
Side by side
- Models. BPC-157 has mostly incisional, burn and sponge data; thymosin beta-4 excisional, diabetic and aged models; GHK-Cu wound chambers, ischaemic flaps and matrix carriers [6,8,15].
- MMP direction. Thymosin beta-4 raised wound MMPs, while topical GHK-Cu wounds had lower MMP-2 and MMP-9 than controls, despite higher fibroblast MMP-2 in culture [11,17,16].
- Molecule tested. The fragment data are non-acetylated; the copper effects may partly reflect copper itself [8,16].
The combination gap
The only published study we located that combined two of these components was in tendon, not skin: after Achilles repair in rats, combined BPC-157 and TB-500 did not confer additional benefits compared with either agent alone [21]. In a PubMed search in October 2026 we found no wound-healing study testing BPC-157, TB-500 and GHK-Cu together, so no published skin model describes the blend.
GLOW BLEND 70mg at PurixLab
GLOW BLEND 70mg: a labelled lyophilized research vial combining BPC-157, TB-500 and GHK-Cu (10mg + 10mg + 50mg, 70mg total per vial), C$136 per vial (CAD, before tax), supplied for laboratory research only. Batch documentation is available on request. Product page: purixlab.com/product/glow-blend-70mg/.
PurixLab ships within Canada only, from stock held in Toronto. Standard shipping is C$15, and shipping is free when the product subtotal is C$200 or more after discounts. Orders outside the GTA ship by Canada Post Xpresspost. Prices are in CAD and taxes are calculated from your shipping address at checkout.
In Toronto and the GTA, our own team delivers orders the same day or the next day. There is no fixed GTA delivery fee: after you place your order, we email you to confirm the delivery time and any delivery charge, and then you pay. There is no storefront or local pickup.
Payment is by Interac e-Transfer (instructions are shown at checkout) or by cryptocurrency through Plisio (Bitcoin, Ethereum, USDT and more): choose Plisio at checkout and you are sent to a secure Plisio payment page after placing the order. Current offers and any pack pricing are shown on the product page and in your cart; offers do not stack.
For laboratory research use only. Not for human or veterinary use, not for consumption, injection or application to skin, and purchasers must be 18 or older. The studies summarised above describe specific materials in published research; they are not claims about any PurixLab product.
Questions or batch documentation requests: [email protected] · Shipping & Delivery · Toronto & GTA delivery · PurixLab FAQ
References
- Seiwerth S, Sikiric P, Grabarevic Z, et al. BPC 157's effect on healing. J Physiol Paris. 1997;91(3-5):173-8. PubMed 9403790 · doi:10.1016/s0928-4257(97)89480-6
- Sikiric P, Separovic J, Anic T, et al. The effect of pentadecapeptide BPC 157, H2-blockers, omeprazole and sucralfate on new vessels and new granulation tissue formation. J Physiol Paris. 1999;93(6):479-85. PubMed 10672992 · doi:10.1016/s0928-4257(99)00123-0
- Mikus D, Sikiric P, Seiwerth S, et al. Pentadecapeptide BPC 157 cream improves burn-wound healing and attenuates burn-gastric lesions in mice. Burns. 2001;27(8):817-27. PubMed 11718984 · doi:10.1016/s0305-4179(01)00055-9
- Huang T, Zhang K, Sun L, et al. Body protective compound-157 enhances alkali-burn wound healing in vivo and promotes proliferation, migration, and angiogenesis in vitro. Drug Des Devel Ther. 2015;9:2485-99. PubMed 25995620 · PMC4425239 · doi:10.2147/DDDT.S82030
- Tkalcević VI, Cuzić S, Brajsa K, et al. Enhancement by PL 14736 of granulation and collagen organization in healing wounds and the potential role of egr-1 expression. Eur J Pharmacol. 2007;570(1-3):212-21. PubMed 17628536 · doi:10.1016/j.ejphar.2007.05.072
- Seiwerth S, Milavic M, Vukojevic J, et al. Stable Gastric Pentadecapeptide BPC 157 and Wound Healing. Front Pharmacol. 2021;12:627533. PubMed 34267654 · PMC8275860 · doi:10.3389/fphar.2021.627533
- Malinda KM, Sidhu GS, Mani H, et al. Thymosin beta4 accelerates wound healing. J Invest Dermatol. 1999;113(3):364-8. PubMed 10469335 · doi:10.1046/j.1523-1747.1999.00708.x
- Philp D, Badamchian M, Scheremeta B, et al. Thymosin beta 4 and a synthetic peptide containing its actin-binding domain promote dermal wound repair in db/db diabetic mice and in aged mice. Wound Repair Regen. 2003;11(1):19-24. PubMed 12581423 · doi:10.1046/j.1524-475x.2003.11105.x
- Kim S, Kwon J. Thymosin beta 4 improves dermal burn wound healing via downregulation of receptor of advanced glycation end products in db/db mice. Biochim Biophys Acta. 2014;1840(12):3452-9. PubMed 25230158 · doi:10.1016/j.bbagen.2014.09.013
- Philp D, Huff T, Gho YS, et al. The actin binding site on thymosin beta4 promotes angiogenesis. FASEB J. 2003;17(14):2103-5. PubMed 14500546 · doi:10.1096/fj.03-0121fje
- Philp D, Scheremeta B, Sibliss K, et al. Thymosin beta4 promotes matrix metalloproteinase expression during wound repair. J Cell Physiol. 2006;208(1):195-200. PubMed 16607611 · doi:10.1002/jcp.20650
- Esposito S, Deventer K, Goeman J, et al. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Test Anal. 2012;4(9):733-8. PubMed 22962027 · doi:10.1002/dta.1402
- Guarnera G, DeRosa A, Camerini R, et al. The effect of thymosin treatment of venous ulcers. Ann N Y Acad Sci. 2010;1194:207-12. PubMed 20536470 · doi:10.1111/j.1749-6632.2010.05490.x
- Treadwell T, Kleinman HK, Crockford D, et al. The regenerative peptide thymosin β4 accelerates the rate of dermal healing in preclinical animal models and in patients. Ann N Y Acad Sci. 2012;1270:37-44. PubMed 23050815 · doi:10.1111/j.1749-6632.2012.06717.x
- Maquart FX, Bellon G, Chaqour B, et al. In vivo stimulation of connective tissue accumulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ in rat experimental wounds. J Clin Invest. 1993;92(5):2368-76. PubMed 8227353 · PMC288419 · doi:10.1172/JCI116842
- Siméon A, Emonard H, Hornebeck W, et al. The tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ stimulates matrix metalloproteinase-2 expression by fibroblast cultures. Life Sci. 2000;67(18):2257-65. PubMed 11045606 · doi:10.1016/s0024-3205(00)00803-1
- Canapp SO, Farese JP, Schultz GS, et al. The effect of topical tripeptide-copper complex on healing of ischemic open wounds. Vet Surg. 2003;32(6):515-23. PubMed 14648529 · doi:10.1111/j.1532-950x.2003.00515.x
- Arul V, Gopinath D, Gomathi K, et al. Biotinylated GHK peptide incorporated collagenous matrix: A novel biomaterial for dermal wound healing in rats. J Biomed Mater Res B Appl Biomater. 2005;73(2):383-91. PubMed 15803494 · doi:10.1002/jbm.b.30246
- Arul V, Kartha R, Jayakumar R. A therapeutic approach for diabetic wound healing using biotinylated GHK incorporated collagen matrices. Life Sci. 2007;80(4):275-84. PubMed 17049946 · doi:10.1016/j.lfs.2006.09.018
- Mulder GD, Patt LM, Sanders L, et al. Enhanced healing of ulcers in patients with diabetes by topical treatment with glycyl-l-histidyl-l-lysine copper. Wound Repair Regen. 1994;2(4):259-69. PubMed 17147644 · doi:10.1046/j.1524-475X.1994.20406.x
- Biçer O, Adanir O, Güleryüz Y, et al. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Jt Dis Relat Surg. 2026;37(3):822-837. PubMed 42542926 · doi:10.52312/jdrs.2026.2951